United Therapeutics Corporation $UTHR Shares Acquired by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC grew its position in United Therapeutics Corporation (NASDAQ:UTHR) by 19.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 7,293 shares of the biotechnology company’s stock after acquiring an additional 1,196 shares during the period. Commonwealth Equity Services LLC’s holdings in United Therapeutics were worth $3,554,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Clearstead Advisors LLC grew its stake in shares of United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 23 shares in the last quarter. Independent Advisor Alliance grew its stake in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after buying an additional 27 shares in the last quarter. Bessemer Group Inc. grew its stake in shares of United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after buying an additional 28 shares in the last quarter. Florida Financial Advisors LLC grew its stake in shares of United Therapeutics by 5.4% in the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 28 shares in the last quarter. Finally, NDVR Inc. grew its stake in United Therapeutics by 5.1% during the 4th quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 30 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,311,581.28. The trade was a 34.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $547.07, for a total value of $4,540,681.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $24,712,246.04. The trade was a 15.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 624,043 shares of company stock valued at $351,930,785 in the last ninety days. Insiders own 8.60% of the company’s stock.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $544.69 on Tuesday. The company has a market capitalization of $23.12 billion, a price-to-earnings ratio of 20.11, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57. The business has a 50-day moving average of $568.47 and a two-hundred day moving average of $519.64. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the firm earned $6.63 earnings per share. As a group, equities research analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on UTHR shares. HC Wainwright boosted their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Raymond James Financial started coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. UBS Group boosted their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Finally, Royal Bank Of Canada lowered their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.